HGH Fragment 176-191
The Lipolytic Fragment of Growth Hormone
Molecular Data
- Formula
- C78H125N23O23S2
- Molecular Weight
- 1817.12 g/mol
01
Overview
HGH Fragment 176-191 is a stabilized analogue of the C-terminal fragment of human growth hormone spanning amino acids 176 to 191. It represents the core of HGH's fat-burning region. Unlike full-length HGH, this fragment does not produce hyperglycemia or tissue growth, making it an ideal isolated lipolytic research compound.
02
Mechanism of Action
The fragment directly activates β3-adrenergic receptors and increases the release of free fatty acids from adipose tissue. It also enhances β-oxidation of fatty acids in muscle and liver. By lacking the N-terminal region, it has no interaction with the GHR that mediates growth-promoting effects.
03
Research Highlights
Preclinical studies in obese rodents show reduction in body weight without changes in IGF-1
Comparison studies with full HGH confirm equivalent or superior lipolytic activity
Safety research demonstrates no diabetogenic effects even at high doses
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue, once or twice daily. Research protocols administer on an empty stomach, morning and/or pre-cardio.
Dosage Guidelines
Cycle Length
4–8 weeks; followed by 2–4 week rest.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
2 mL added to a 5 mg vial
Concentration
2.5 mg/mL (2,500 mcg/mL)
Storage
Refrigerate at 2–8 °C; protect from light. Discard 30 days after reconstitution.
Notes
Fragment 176–191 retains the lipolytic region of hGH without IGF-1 or diabetogenic effects. Fast 30 minutes pre- and post-dose.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
HGH Fragment 176-191 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
HGH Fragment 176-191 Knowledge Graph
Explore how HGH Fragment 176-191 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
HGH Fragment 176-191 — Common Research Questions
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a stabilized analogue of the C-terminal fragment of human growth hormone spanning amino acids 176 to 191. It represents the core of HGH's fat-burning region. Unlike full-length... HGH Fragment 176-191 belongs to the Weight Loss research category and is studied for its the lipolytic fragment of growth hormone.
How does HGH Fragment 176-191 work?
The fragment directly activates β3-adrenergic receptors and increases the release of free fatty acids from adipose tissue. It also enhances β-oxidation of fatty acids in muscle and liver. By lacking the N-terminal region, it has no interaction with the GHR that mediates growth-promoting effects.
What are the key research benefits of HGH Fragment 176-191?
Potent stimulation of fat breakdown (lipolysis). No effect on insulin sensitivity or blood glucose. Inhibition of new fat formation (lipogenesis). Potential cartilage repair effects. No mitogenic or proliferative effects. Highly selective metabolic action.
What is the molecular structure of HGH Fragment 176-191?
HGH Fragment 176-191 has the molecular formula C78H125N23O23S2 and a molecular weight of 1817.12 g/mol. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about HGH Fragment 176-191?
Preclinical studies in obese rodents show reduction in body weight without changes in IGF-1 Comparison studies with full HGH confirm equivalent or superior lipolytic activity Safety research demonstrates no diabetogenic effects even at high doses These findings are based on preclinical and clinical research. HGH Fragment 176-191 is a research compound and these studies do not constitute medical advice.
Is HGH Fragment 176-191 FDA approved?
No. HGH Fragment 176-191 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does HGH Fragment 176-191 belong to?
HGH Fragment 176-191 belongs to the Weight Loss category, which focuses on compounds studied for their roles in metabolic regulation, growth hormone signaling, and targeted adipose tissue reduction. You can explore more compounds in this category on the Weight Loss pillar page.
Related Articles
Tesamorelin: Clinical Data for Visceral Fat Reduction
Phase III trial data showing 15-18% visceral fat reduction and the FDA approval rationale for Egrifta®.
AOD-9604: Lipolysis Without Growth Effects
How AOD-9604's C-terminus fragment of HGH stimulates lipolysis without the growth-promoting effects of full-length HGH.
CJC-1295 + Ipamorelin: Synergistic GH Secretagogue Research
Examining the complementary mechanisms of CJC-1295 (GHRH analogue) and Ipamorelin (ghrelin mimetic) in research settings.
Scientific References
Heffernan et al. — "HGH fragment 176-191 lipolytic action" (Mol Cell Endocrinol, 2003)
Comparison studies vs full-length HGH, Endocrinology, 2001
Preclinical studies in obese rodents show reduction in body weight without changes in IGF-1
Comparison studies with full HGH confirm equivalent or superior lipolytic activity
Safety research demonstrates no diabetogenic effects even at high doses